Satisfaction and quality of life issues in patients receiving urethral botulinum toxin A injections for detrusor sphincter dyssynergia and detrusor botulinum toxin A injections for neurogenic detrusor overactivity  by Wang, Chung-Cheng & Kuo, Hann-Chorng
at SciVerse ScienceDirect
Tzu Chi Medical Journal 25 (2013) 195e199Contents lists availableTzu Chi Medical Journal
journal homepage: www.tzuchimedjnl .comReview ArticleSatisfaction and quality of life issues in patients receiving urethral
botulinum toxin A injections for detrusor sphincter dyssynergia and
detrusor botulinum toxin A injections for neurogenic detrusor
overactivity
Chung-Cheng Wang a,b,c, Hann-Chorng Kuo d,e,*
aDepartment of Urology, En Chu Kong Hospital, New Taipei City, Taiwan
bDepartment of Urology, College of Medicine, National Taiwan University, Taipei, Taiwan
cDepartment of Biomedical Engineering, Chung Yuan Christian University, Taoyuan, Taiwan
dDepartment of Urology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan
e School of Medicine, Tzu Chi University, Hualien, Taiwana r t i c l e i n f o
Article history:
Received 24 April 2013
Received in revised form
14 May 2013
Accepted 15 May 2013
Keywords:
Botulinum toxin
Detrusor sphincter dyssynergia
Neurogenic bladderConﬂict of interest: none.
* Corresponding author. Department of Urology, Bu
pital, 707, Section 3, Chung-Yang Road, Hualien, Taiwan
fax: þ886 3 8560794.
E-mail address: hck@tzuchi.com.tw (H.-C. Kuo).
1016-3190/$ e see front matter Copyright  2013, Bu
http://dx.doi.org/10.1016/j.tcmj.2013.05.003a b s t r a c t
Detrusor sphincter dyssynergia (DSD) and neurogenic detrusor overactivity (NDO) are common condi-
tions in patients with spinal cord injury, multiple sclerosis, and transverse myelitis. With advancements
in the clinical application of botulinum toxin A (onabotulinumtoxinA, BoNT-A) injections in the treat-
ment of chronic lower urinary tract dysfunction, there has been much improvement in the management
of DSD and NDO. Therefore, we reviewed the current literature with focus on subjective outcomes and
patient satisfaction scores after BoNT-A treatment. We searched PubMed for articles on the management
of neurogenic bladder using the following keywords: DSD, NDO, BoNT-A, satisfaction, dissatisfaction,
quality of life, urodynamics, and lower urinary tract dysfunction. Patients receiving BoNT-A urethral
injections for DSD have improvements in voiding volume, decreased postvoid residual (PVR) urine, and
maximal urethral pressure. Most patients are satisﬁed and beneﬁt from less difﬁcult urination. However,
some patients are dissatisﬁed with increased urinary incontinence. The BoNT-A detrusor injections for
NDO can signiﬁcantly increase reﬂex volume and maximal bladder capacity as well as decrease unin-
hibited bladder contractions. Most patients are satisﬁed with reduced urinary incontinence. However,
some patients are dissatisﬁed with increased volumes of PVR urine and more difﬁcult urination.
Although published clinical studies usually include only a small number of patients and lack randomi-
zation and placebo-controlled groups, they provide important evidence of subjective improvement in the
management of patients with DSD and NDO using BoNT-A injections. Urologists should inform patients
about the main therapeutic effects and possible disadvantages of BoNT-A injections.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
“Chung” means bent neither one way or another, and “Yung”
represents unchanging.
Doctrine of the Mean, Confucius 551e479 BC
The micturition cycle involves two relatively separate processes,
namely, (1) bladder ﬁlling and urine storage and (2) bladderddhist Tzu Chi General Hos-
. Tel.: þ886 3 8561825x2113;
ddhist Compassion Relief Tzu Chiemptying. Bladder ﬁlling requires accommodation of increasing vol-
umes of urine at a low intravesical pressure, a closed bladder outlet,
and absence of involuntary bladder contractions. Bladder emptying
requires an adequate magnitude of bladder contraction and a
concomitant lower outlet resistance [1]. The balance and coordina-
tion between bladder and bladder outlet contribute to the normal
function of the lower urinary tract. However, in cases of detrusor
sphincter dyssynergia (DSD) and neurogenic detrusor overactivity
(NDO),which are commonly found inpatientswith spinal cord injury
(SCI), multiple sclerosis, and transverse myelitis, the balance cannot
be maintained and lower urinary tract dysfunction occurs [2].
Patients with DSD often have voiding difﬁculty, elevated intra-
vesical pressure, and a greater volume of postvoid residual urineFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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zation. Long-term complications are repeated urinary tract in-
fections (UTIs), upper urinary tract damage, and vesical stone
formation [3]. In addition, patients with NDO usually have urgency,
nocturia, and urge incontinence. These adverse events cause poor
quality of life (QOL), high health-service costs, and depression in
these patients.
Recently, botulinum toxin A (BoNT-A) has emerged as a novel
treatment for DSD and NDO in patients who are refractory to
conventional treatment methods [4e8]. Results of several studies
have shown that urethral injections of BoNT-A can reduce urethral
resistance and possibly restore bladder emptying [4]. Detrusor in-
jections of BoNT-A can reduce episodes of urge urinary inconti-
nence, decrease neurogenic NDO, and improve bladder compliance
[8]. However, detrusor injections of BoNT-A usually induce detrusor
underactivity, increase the PVR, and even cause urinary retention
[9]. Patients may need periodic clean intermittent catheterization
(CIC) and repeated UTI can become a de novo problem. By contrast,
urethral injections may cause undesired exacerbation of urinary
incontinence, although the PVR volume can be reduced [10]. For a
patient with both storage and voiding dysfunction, choosing be-
tween being “continent with CIC” and “incontinent with sponta-
neous voiding” is difﬁcult.
The priorities in managing neurogenic bladder dysfunction
should not only be based on improvement of urodynamic param-
eters, freedom from indwelling catheters, and preservation of renal
function, but should also consider the patient’s needs and prefer-
ences, hand function, ability to perform CIC, and family support
[11]. Patient-reported outcomes, including health-related QOL, goal
attainment, and treatment expectations, are important consider-
ations and it is necessary to inform patients about the possible
advantages and disadvantages of BoNT-A treatment [12]. Here, we
review recent evidence on satisfaction and QOL issues in patients
with DSD receiving urethral BoNT-A injections and in patients with
NDO receiving detrusor BoNT-A injections.
2. Satisfaction and QOL after urethral BoNT-A injections for
DSD
In 1988, Dykstra and colleagues ﬁrst reported on a treatment
method involving administration of 100 U onabotulinumtoxinA
(Allergan, Irvine, CA, USA) injections into the external sphincter of
11 patients with SCI and DSD [13]. Eight (72%) of these patients
beneﬁted from the therapeutic effects of the injection for an
average of 50 days. In these patients, the maximal urethral pressure
decreased by 27 cmH2O and the PVR volume decreased by 146 mL.
Subsequent studies also showed signiﬁcant improvements in the
voided volume, PVR volume, and maximum urethral pressure
[4,7,14]. Similar effects were noted with transrectal ultrasound-
guided botulinum toxin injection [15]. Recovery of spontaneous
micturition was noted in approximately 50e70% of patients.
However, there were rare reports of worsening urinary inconti-
nence and QOL (Table 1) [7,10,16].Table 1
Subjective outcome and satisfaction in patients receiving botulinum toxin A urethral inj
Study No. of
patients
BoNT-A type, dose Follow-up
duration (m
de Sèze et al [7] (2002) 13 100 U onabotulinumtoxinA 1
Schulte-Baukloh et al
[16] (2005)
22 50e100 U onabotulinumtoxinA 3
Kuo [10] (2008) 33 100 U onabotulinumtoxinA 3
BoNT-A ¼ botulinum toxin A; IIQ-7 ¼ Incontinence Impact Questionnaire 7-item; SII ¼ S
Inventory 6-item Short Form.In 2002, de Sèze et al ﬁrst compared satisfaction and urody-
namic changes between ﬁve SCI patients receiving onabotuli-
numtoxinA urethral injections and eight receiving lidocaine
injections [7]. The BoNT-A group had signiﬁcantly higher scores for
satisfaction (6.8  0.9 vs. 3.4 1.0, p¼ 0.02) and fewer cases of PVR
(105  100 vs. 263  116, p ¼ 0.01) than the lidocaine group.
Reinjection was necessary in all eight patients (100%) in the lido-
caine group, but in only one (20%) patient in the BoNT-A group.
In 2005, Schulte-Baukloh et al injected onabotulinumtoxinA
into dual positions, the urethra and bladder, for overactive bladder
syndrome [16]. There were signiﬁcant reductions (16e43%) in the
scores of the three questionnaires used for evaluation [Urogenital
Distress Inventory 6-item Short Form (UDI-6), The Symptom
Severity Index, and The Symptom Impact Index] from 1 to 6
months. The overall satisfaction rate was as high as 86%. Noticeable,
the volume of PVR of the patients after dual injections was
distinctly less than that of the patients receiving detrusor injections
alone.
In 2008, Kuo comprehensively demonstrated an increased
maximum ﬂow rate and decreased PVR and maximal voiding
pressure 3 months after treatment with urethral sphincter in-
jections of 100 U onabotulinumtoxinA [10]. Compared with base-
line, the Incontinence Impact Questionnaire 7-item (IIQ-7) score
(baseline vs. 3 months, 19.0  2.4 vs. 17.1  2.9, p ¼ 0.001) signiﬁ-
cantly improved but the UDI-6 (baseline vs. 3 months, 8.6  2.7 vs.
7.9  3.7, p ¼ 0.25) score remained about the same. Less difﬁcult
urination and a decreased PVR volume were noted in 78.8% and
69.7% of the patients, respectively. However, increased urinary in-
continence and persistent difﬁculty in urination were found in
48.5% and 21.2% of the patients, respectively (Table 2). The overall
satisfaction rate was 61%.
3. Satisfaction and QOL after detrusor BoNT-A injections for
NDO
In 2000, Schurch et al studied 21 SCI patients with NDO
receiving detrusor 200 Ue300 U onabotulinumtoxinA injections
[17]. After 6 weeks of follow-up, 19 patients were found to be fully
continent. Of these, six patients were able to stop anticholinergic
drug therapy, and the remaining 13 were able to reduce the dose by
half. Urodynamic studies found a signiﬁcant increase in the reﬂex
volume and maximal bladder capacity and a signiﬁcant decrease in
the maximal detrusor pressure during uninhibited bladder con-
tractions. No side effects were observed.
In recent years, data from several randomized, double-blind,
placebo-controlled trials have demonstrated similar ﬁndings
compared with placebo. A single detrusor injection of either 200 or
300 U onabotulinumtoxinA improved overactive bladder symp-
toms, urodynamic parameters, and QOL [18e20]. Despite hetero-
geneous study designs, almost all of these studies showed
signiﬁcant improvement in incontinence episodes, maximum cys-
tometric capacity, and bladder compliance. The mean duration of
efﬁcacy in single-injection trials was 8 months (range: 12e36ection for detrusor sphincter dyssynergia.
o)
Subjective measures Subjective outcomes Satisfaction
rate
Satisfaction score (1e10) Mean satisfaction score: 6.3 NA
UDI-6, SSI, SII, satisfaction
scale (0e10)
YUDI-6 (25e70%), satisfaction
scale: 6.6
86%
UDI-6, IIQ-7 No difference in UDI-6, YIIQ-7
(10%)
61%
ymptom Impact Index; SSI ¼ Symptom Severity Index; UDI-6 ¼ Urogenital Distress
Table 4
Main therapeutic effect and causes of dissatisfaction after BoNT-A urethral detrusor
injection for patients with neurogenic detrusor overactivity.
Main therapeutic effect Patients (%) Causes of dissatisfaction Patients (%)
Decreased incontinence 45 (90) Increased PVR 25 (50)
Increased bladder capacity 36 (72) Difﬁcult urination 16 (32)
Fewer urgency episodes 31 (62) Nocturnal incontinence 10 (20)
Complete dryness 29 (58) Severe incontinence 6 (12)
Less autonomic dysreﬂexia 5 (71) Needing CIC 5 (10)
BoNT-A ¼ botulinum toxin A; CIC ¼ clean intermittent catheterization;
PVR ¼ postvoid residual.
Table 2
Main therapeutic effect and causes of dissatisfaction after botulinum toxin A ure-
thral sphincter injection for patients with detrusor sphincter dyssynergia.
Less difﬁcult urination 26 (78.8) Increased urinary incontinence
Decreased PVR 23 (69.7) Persistent difﬁculty in urination
Less CIC 7 (21.2) Increased urgency
Less autonomic dysreﬂexia 2 (50) De novo frequency
Less UTI 10 (67) d
BoNT-A ¼ botulinum toxin A; CIC ¼ clean intermittent catheterization;
PVR ¼ postvoid residual; UTI ¼ urinary tract infection.
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open-label studies [21,22].
The primary and secondary end points of previous studies
mainly focused their attention on changes in parameters in voiding
diaries and urodynamic studies. A limited number of studies eval-
uated the therapeutic satisfaction and QOL in patients with NDO
who received detrusor BoNT-A injections. Table 3 [20,23e25]
summarizes the subjective measures and satisfaction rate in
recent NDO clinical trials. Most studies used the UDI-6, IIQ-7, and
Incontinence Quality of Life and Satisfaction scales as subjective
variables. The overall satisfaction rate was approximately 69e83%
[20,23e25].
In 2007, Ghalayini and Al-Ghazo from Jordan assessed NDO
patient satisfaction with 500 U DYSPORT (Ipsen Biopharm Ltd,
Slough, Berkshire, UK) intradetrusor injections using a 5-point scale
(1¼ very dissatisﬁed; 2¼ dissatisﬁed; 3¼ undecided; 4¼ satisﬁed;
and 5 ¼ very satisﬁed) [24]. The satisfaction score signiﬁcantly
increased at 6 weeks compared with baseline (1.6  0.5 vs.
3.8  1.0, p ¼ 0.002). However, the underlying reasons for satis-
faction or dissatisfactionwere not revealed. In 2008, Kuo reported a
signiﬁcantly increased maximal bladder capacity and PVR and
decreased detrusor pressure 3 months after 200 U onabotuli-
numtoxinA detrusor injections in patients with NDO [23]. Signiﬁ-
cant improvements in the UDI-6 and IIQ-7 scores were also
reported at 3 months. Forty-ﬁve (90%) patients had decreased in-
continence and 36 (72%) patients had increased bladder capacity.
However, 25 (50%) were dissatisﬁed with increased PVR and 16
(32%) had more difﬁcult urination or urinary retention. The overall
satisfaction rate was 78% (Table 4).
In 2009, Hori et al evaluated patients’ perspective (n ¼ 72) on
whether they would consider BoNT-A injections as a long-term
treatment option for managing their NDO secondary to SCI [25].
Of them, 67% agreed to repeated injections and 69% were either
satisﬁed or very satisﬁed with their treatment. The mean patient
satisfaction score was 6.2 (1 ¼ not satisﬁed; 10 ¼ very satisﬁed). Of
interest, younger patients were likely to choose this option at a laterTable 3
Subjective outcome and satisfaction in patients receiving botulinum toxin A detrusor inj
Study No. of
patients
BoNT type and dose Follow-up
duration
Subjec
Ghalayini and Al-Ghazo
[24] (2007)
14 500 U DYSPORT 6 wk Satisfa
Kuo [23] (2008) 50 200 U onabotulinumtoxinA 3, 6 mo UDI-6
grade,
and sa
Hori et al [25] (2009) 72 750 U and 1000 U
DYSPORT
7 mo Satisfa
Sussman et al [20] (2013) 275 Placebo and 200 U,
300 U onabotulinumtoxinA
6 and 12 wk I-QOL
I-QOL ¼ Incontinence-Related Quality of Life; IIQ-7 ¼ Incontinence Impact Questionn
Questionnaire; PGA ¼ Patient Global Assessment; UDI-6 ¼ Urogenital Distress Inventoryinterval than those who were older. Recently, a level A evidence
study showed that BoNT-A signiﬁcantly reduced urinary inconti-
nence and improved urodynamics and QOL in patients with NDO
[20]. During week 6, 7.6%, 38.0%, and 39.6% of patients in the pla-
cebo, 200 U, and 300 U onabotulinumtoxinA groups, respectively,
were fully dry. Themean changes from baseline in the Incontinence
Quality of Life total scores were signiﬁcantly higher in the 200 U
(24.4) and 300 U (24.3) onabotulinumtoxinA groups than the pla-
cebo group (11.7).
4. Urethral injections for DSD, detrusor injections for NDO, or
dual injections?
Both DSD and NDO commonly occur in patients with SCI and
multiple sclerosis. The DSD causes voiding problems such as
micturition difﬁculty, abdominal straining, and an increased PVR
volume. Thus, some patients need to perform CIC to empty their
bladders periodically. Recent evidence has suggested that urethral
sphincter BoNT-A injections can decrease urethral resistance and
possibly restore physiological voiding. However, increased incon-
tinence is an important concern, and up to 48% patients have uri-
nary incontinence, even though their voiding function has
improved. By contrast, NDO induces storage problems such as
frequency, urgency, and urinary incontinence. Although detrusor
BoNT-A injections can provide clinical and urodynamic improve-
ment, an increased PVR and/or urinary retention usually occurs and
some patients might be disappointed by the development of de
novo problems that they did not expect.
Is it possible to consider both continence and appropriate
voiding to achieve the maximum satisfaction rate for SCI patients
with DSD and NDO? In 2005, Schulte-Baukloh et al showed that
dual BoNT-A urethra and detrusor injections in patients with re-
fractory overactive bladder could improve the micturition volume,
daytime frequency, and pad use [16]. Changes in the PVR volume
were not statistically signiﬁcant during follow-ups at 4th week and
3rd month. No patient had to use a catheter to empty the bladder.ection for neurogenic detrusor overactivity.
tive measures Subjective outcomes Satisfaction rate
ction scale (1e5) Mean satisfaction scale: 3.8 83%
, IIQ-7, incontinence
voiding difﬁculty grade
tisfaction score (0, 1, 2, 3)
Y UDI-6, YIIQ-7, 90%Yincontinence,
32%[voiding difﬁculty
78%
ction score (1e10) Mean satisfaction score: 6.2 69%
, OAB-PSTQ, PGA [I-QOL (25%), YOAB-PSTQ
(approximately 30e40%), PGA
(approximately 50e80%)
improvement
Approximately
70e80%
aire 7-item; OAB-PSTQ ¼ Overactive Bladder-Patient Satisfaction with Treatment
6-item Short Form.
Table 5
Differences in opinions between the sexes in the management of neurogenic
bladder.
Female Male
Most bothersome Severe incontinence Greater PVR urine volume,
voiding difﬁculty
Continence device Diaper External appliance or diaper
Treatment goal Stay dry and avoid
diaper use
Voiding by abdominal tapping
Treatment
suggestion
Approximately
200 Ue300 U
onabotulinumtoxinA
detrusor injection
200 U onabotulinumtoxinA
detrusor injection with/without
100 U onabotulinumtoxinA
urethral injection
BoNT-A ¼ botulinum toxin A; PVR ¼ postvoid residual urine.
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incontinence after injection. On an average, the score for urine
control (1 ¼ better, 2 ¼ same, and 3 ¼ worse) improved by 1.30
compared with that before injection therapy, and 86% of the pa-
tients were satisﬁed and would choose the procedure for their
bladder condition.
Multiple considerations and tailor-made therapeutic plans are
necessary before administering BoNT-A injections. For example,
patients with high cervical SCI or poor hand function might not be
able to perform CIC. Support from a readily available caregiver is
very helpful for patients after they receive intradetrusor BoNT-A
injections for NDO. Otherwise, urethral injections may be a better
solution for DSD. The CIC can be avoided and an external device can
be used to prevent incontinence [10,23]. In addition, in cases of
severe urge incontinence and refractory diaper dermatitis, com-
plete dryness with CIC may be preferable, and higher doses of
intradetrusor BoNT-A injections are suggested. Physicians should
evaluate patients’ hand dexterity, abdominal muscle power,
bladder sensation, the degree of DSD and NDO, and family and
economic support and communicate well with patients to design
an appropriate treatment protocol. Patient satisfaction is deter-
mined by many factors, such as improvement in incontinence, the
burden of CIC, improvement in difﬁcult urination, de novo prob-
lems, and meeting initial expectations. Improvement in objective
parameters is not completely correlated with subjective thera-
peutic satisfaction. Management of voiding dysfunction and in-
continence in patients with DSD and NDO is a great challenge for
urologists.
Gender is another important consideration for management of
neurogenic lower urinary tract dysfunction (Table 5). Female SCI
patients usually have more severe urinary incontinence and use
diaper protection. Therefore, the desire to become dry to avoid use
of diapers is a great therapeutic goal for women. Higher doses of
onabotulinumtoxinA detrusor injections (200 or 300 U) are sug-
gested and “continence with CIC” is a more accepted therapeutic
choice for female patients. By contrast, male SCI patients have
greater PVR volume and can use external appliances more easily to
prevent wetting underwear. “Incontinence without CIC” is a more
acceptable compromise than “performing CIC” for male patients
with SCI. Thus, 200 U or lower doses of onabotulinumtoxinA
detrusor injections are suggested. In addition, addition urethral or
bladder neck injections to improve emptying function are also
recommended for male patients [26].
5. Conclusion
In the era of BoNT-A, urethral injections to reduce bladder outlet
resistance, detrusor BoNT-A injections to decrease bladder unin-
hibited contractions, and combined injections are effective treat-
ments for patients with DSD and NDO. Physicians should discussthe main therapeutic effects and possible disadvantages with pa-
tients before commencing treatment. A complete understanding of
the patient’s preferences for management, their hand function, and
capacity for self-care, and social, economic and family support can
bring about better QOL. Achieving the “balance” in Chinese ancient
wisdom between storage and emptying functions can beneﬁt most
patients with DSD and NDO.References
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